Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-confirmation phase II study of 68Ga-OPS202 PET imaging in GEP-NET
2016-004928-39Phase 2Completed
- Sponsor
- Ipsen
- Start
- Mar 2017
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptide-Drug Conjugates → Peptide Conjugates → Peptides
- Countries
- 1
01
Overview
Phase 2, randomised trial of satoreotide in Gastroenteropancreatic Carcinoid Tumor (4 arms), sponsored by Ipsen. Primary endpoint: Efficacy. Started Mar 2017; status: completed.
02
Drugs
satoreotide
03
Conditions
Gastroenteropancreatic Carcinoid Tumor
Beyond the preview
Go deeper on 2016-004928-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004928-39.